Grants and Contributions:
Title:
Using Exosomes to Deliver siRNA Across the Blood-Brain-Barrier to Treat Parkinson's Disease
Agreement Number:
925191
Agreement Value:
$25,000.00
Agreement Date:
Mar 15, 2019 - Mar 31, 2020
Description:
Accumulation of toxic forms of alpha-synuclein plays a central role in the development of Parkinson's disease. We aim to harness the ability of cells' own nanovesicles to cross the blood-brain barrier, silence alpha-synuclein and protect nerve cells, paving the way for novel therapeutics for silencing key toxic genes in other neurodegenerative diseases
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators.
Location:
Ottawa, Ontario, CA K1N 6N5
Reference Number:
172-2018-2019-Q4-00044
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
119278877
Recipient Type:
Academia
Recipient's Operating Name:
University of Ottawa
Recipient's Legal Name:
University of Ottawa
Federal Riding Name:
Ottawa--Vanier
Federal Riding Number:
35078
Program:
Collaborative Science, Technology and Innovation Program – Ideation Fund
Program Purpose:
The Ideation Fund is intended to encourage, test and validate transformative research ideas generated by teams of NRC scientific personnel and external collaborators with complementary capabilities, acting as a demonstration phase for a continually-evolving suite of research and development (R&D) deliverables at the NRC. The fund supports exploratory research through two mechanisms: the New Beginnings Initiative and the Small Teams Initiative.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences